Sunday, September 26 2021

-Mitali Stevens, PharmD., BCPS., Joins MCRA as Director, Reimbursement Strategy and Evidence Development.

WASHINGTON, September 15, 2021 / PRNewswire / – MCRA, LLC, a leading medical device and biological consultancy and clinical research organization (CRO) integrating U.S. and international regulation, clinical research, reimbursement, healthcare compliance, l quality assurance and cybersecurity is pleased to announce Mitali stevens, PharmD., BCPS., Joined MCRA as Director, Reimbursement Strategy and Evidence Development.

MCRA logo (PRNewsFoto / MCRA)

With over 20 years of clinical pharmacy, reimbursement and market access experience, Dr Stevens has focused his career on understanding stakeholder needs and developing evidence for optimal product positioning and market adoption. . Dr Stevens recently joined the MCRA after working at Edward Lifesciences, where she was responsible for developing HEOR strategies and implementing market access tactics that demonstrate the clinical and economic value of the products for the Division of intensive care. Prior to joining Edwards, Dr Stevens served as the field liaison supporting managed markets, medical affairs, and health economics research and outcomes for various pharmaceutical companies, where she executed the value proposition HEOR through research publications and presentations of scientific data forms and business models. to key stakeholders in managed care organizations, IDNs, ACOs, LTCs, GPOs, PBMs and home health care.

In his role at MCRA, Dr. Stevens will support our clients in the development and execution of systematic evidence generation strategies that integrate health economics, outcome research and market access solutions to all. the stages of the product life cycle, which is an essential element for new technologies to be achieved. wide market adoption. Specifically, Dr Stevens will assist our clients with a systematic approach to evidence development, starting with an assessment of current market needs and performing gap analyzes to develop a streamlined evidence plan that takes into account relevant feedback. stakeholders, to ensure a competitive advantage and a value proposition. that supports commercial adoption. The evidence plan will be executed through close collaboration with MCRA’s Clinical Research Organization (CRO) and / or through real-world data analysis, followed by the development of valuable communication tools for engagement stakeholders that can be leveraged to better understand future evidence development needs. as part of ongoing feedback.

Vice President of the MCRA, Reimbursement, Health Economics and Market Access, Tonya Dowd said: “I am delighted to have Dr Stevens on our team. Dr. Stevens ‘role is the keystone for successful market adoption and ultimately patient access to our customers’ valuable technologies. “

Dr Stevens said: “The goal of producing evidence is to improve patient care by changing the mindset of clinicians, but developing critical evidence that addresses the concerns of multiple stakeholders. remains a challenge. It requires a concerted effort across all functions within an organization to ensure that when a product is marketed, reimbursement is established in a well-developed market. Earlier engagement with key stakeholders enables systematic identification of gaps and barriers, and I am honored to work with each of MCRA’s service divisions to streamline product development for a holistic market access strategy that enables achieve our clients’ business goals.

About MCRA, LLC: MCRA is the leading independent clinical research organization (CRO) and independent medical device and biological consultancy firm. MCRA offers its clients the industry experience by integrating five creators of business value: regulation, clinical research, reimbursement, healthcare compliance and quality assurance to provide a dynamic and leading effort on the market, from concept to commercialization. MCRA’s integrated application of these key value-creating initiatives delivers unmatched value to its clients. MCRA has offices at Washington DC, Hartford, Connecticut, and New York, New York State, and serves more than 700 clients worldwide. His main areas of therapeutic experience include orthopedics, spine, cardiovascular devices, diagnostic imaging, wound care, artificial intelligence, dental care, general surgery, digital health, neurology, robotics and in vitro diagnostic (IVD) devices as well as cybersecurity of medical devices. www.mcra.com

About Viscogliosi Brothers, LLC: Viscogliosi Brothers, LLC (VB), founded MCRA in 2004. VB is headquartered in New York City and specializes in financing venture capital, private equity and investment banking activities for the neuromusculoskeletal industry. VB is dedicated to financing innovation in the health sector. www.vblc.com

For more information please contact:

Alyssa howard
Senior Director, Business Development
Telephone: 215.870.3952
Email: [email protected]

Cision

Cision

View original content to download multimedia: https://www.prnewswire.com/news-releases/mcra-expands-evidence-generation-service-line-to-ensure-early-stakeholder-engagement-for-optimal-product -adoption -301377916.html

SOURCE MCRA, LLC


Source link

Previous

Canara Bank and LIC Housing Finance among stocks under F&O ban on NSE today

Next

Former Kamala Harris Campaign Finance Chairman Plans to Reinvent the Way CEOs Approach Diversity in U.S. Businesses with New Consulting Firm

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also